Latest News
StageBio Partners with Preclinical Medical Device Laboratory Alizée Pathology
Thursday 14 November 2019

14 November 2019 - US-based biopharmaceutical, medical device and contract research services provider StageBio has merged with Maryland, US-based preclinical CRO Alizée Pathology, the company said.
Terms of the transaction were not disclosed.
StageBio said Alizée's expertise will grow the company's list of offerings.
The broad client base and services at StageBio, combined with the speciality expertise at Alizée, adds laboratory space in Thurmont and Cumberland Maryland, as well as staff with experience in speciality medical devices and biomarkers/biologics that will complement the StageBio team based in Virginia, Massachusetts, Ohio, and Maryland.
The combined company now employs 28 board-certified veterinary pathologists with a total employee base of over 150.
StageBio, a portfolio company of Ampersand Capital, is the provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries.
Alizée Pathology is a preclinical medical device laboratory in North America. Alizée provides GLP-compliant services in support of the development of novel devices and therapeutics.
Ampersand Capital Partners is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector.
Date Published: 14/11/2019
Target: Aliz, ée Pathology
Country: USA
Sector: Healthcare
Type: LBO
Status: Closed
Buyer: StageBio
Terms of the deal were not disclosed